Vitamin D supplements: A novel therapeutic approach for Alzheimer patients

Frontiers in Pharmacology

Volumn 5 JAN, Issue , 2014, Pages

  Annweiler, Cedric ^a,b   Karras, Spyridon N ^c   Anagnostis, Panagiotis ^c   Beauchet, Olivier ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Alzheimer disease; Dementia; Disease modifying drug; Memantine; Multi target drug; Neuroendocrinology; Research; Vitamin D

Indexed keywords

BAPINEUZUMAB; CHOLINESTERASE INHIBITOR; MEMANTINE; VITAMIN D; VITAMIN D RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM; DISEASE SEVERITY; DRUG COMBINATION; DRUG MECHANISM; DRUG RESEARCH; GLIA CELL; HUMAN; HYPOVITAMINOSIS D; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; PREVALENCE; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84893516215     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00006     Document Type: Article

References (31)

1. Aisen, P. S. (2010). Pre-dementia Alzheimer's trials: overview. J. Nutr. Health Aging 14, 294. doi: 10.1007/s12603-010-0065-2.
2. Anand, R., Gill, K. D., and Mahdi, A. A. (2014). Therapeutics of Alzheimer's disease: past, present and future. Neuropharmacology 76, 27-50. doi: 10.1016/j.neuropharm.2013.07.004.
3. Annweiler, C., Allali, G., Allain, P., Bridenbaugh, S., Schott, A. M., Kressig, R. W., et al. (2009). Vitamin D and cognitive performance in adults: a systematic review. Eur. J. Neurol. 16, 1083-1089. doi: 10.1111/j.1468-1331.2009.02755.x.
4. Annweiler, C., and Beauchet, O. (2011). Vitamin D-mentia: randomized clinical trials should be the next step. Neuroepidemiology 37, 249-258. doi: 10.1159/000334177.
5. Annweiler, C., and Beauchet, O. (2012). Possibility of a new anti-alzheimer's disease pharmaceutical composition combining memantine and vitamin D. Drugs Aging 29, 81-91. doi: 10.2165/11597550-000000000-00000.
6. Annweiler, C., Brugg, B., Peyrin, J. M., Bartha, R., and Beauchet, O. (2014). Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. Neurobiol. Aging 35, 331-335. doi: 10.1016/j.neurobiolaging.2013.07.029.
7. Annweiler, C., Montero-Odasso, M., Llewellyn, D. J., Richard-Devantoy, S., Duque, G., and Beauchet, O. (2013a). Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J. Alzheimers Dis. 37, 147-171. doi: 10.3233/JAD-130452.
8. Annweiler, C., Llewellyn, D. J., and Beauchet, O. (2013b). Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 33, 659-674. doi: 10.3233/JAD-2012-121432.
9. Annweiler, C., Rolland, Y., Schott, A. M., Blain, H., Vellas, B., Herrmann, F. R., et al. (2012a). Higher vitamin D dietary intake is associated with lower risk of Alzheimer's disease: a 7-year follow-up. J. Gerontol. A Biol. Sci. Med. Sci. 67, 1205-1211. doi: 10.1093/gerona/gls107.
10. Annweiler, C., Fantino, B., Gautier, J., Beaudenon, M., Thiery, S., and Beauchet, O. (2012b). Cognitive effects of vitamin D supplementation in older outpatients visiting a memory clinic: a pre-post study. J. Am. Geriatr. Soc. 60, 793-795. doi: 10.1111/j.1532-5415.2011.03877.x.
11. Annweiler, C., Herrmann, F. R., Fantino, B., Brugg, B., and Beauchet, O. (2012c). Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn. Behav. Neurol. 25, 121-127. doi: 10.1097/WNN.0b013e31826df647.
12. Annweiler, C., Schott, A. M., Berrut, G., Chauviré, V., Le Gall, D., Inzitari, M., et al. (2010). Vitamin D and ageing: neurological issues. Neuropsychobiology 62, 139-150. doi: 10.1159/000318570.
13. Annweiler, C., Souberbielle, J. C., Schott, A. M., de Decker, L., Berrut, G., and Beauchet, O. (2011). Vitamin D in the elderly: 5 points to remember. Geriatr. Psychol. Neuropsychiatr. Vieil. 9, 259-267. doi: 10.1684/pnv.2011.0288.
14. Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. CD005593. doi: 10.1002/146
15. Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., et al. (2008). Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51, 347-372. doi: 10.1021/jm7009364.
16. de Sant'Anna, M., and Morat, B. (2013). Non-drug-based management of Alzheimer's disease. Soins Gerontol. 102, 15-18.
17. Etgen, T., Sander, D., Bickel, H., Sander, K., and Förstl, H. (2012). Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dement. Geriatr. Cogn. Disord. 33, 297-305. doi: 10.1159/000339702.
18. Gezen-Ak, D., Dursun, E., Ertan, T., Hanagasi, H., Gürvit, H., Emre, M., et al. (2007). Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J. Exp. Med. 212, 275-282. doi: 10.1620/tjem.212.275.
19. Holick, M. F. (2007). Vitamin D deficiency. N. Engl. J. Med. 357, 266-281. doi: 10.1056/NEJMra070553.
20. Johansson, P., Almqvist, E. G., Johansson, J. O., Mattsson, N., Andreasson, U., Hansson, O., et al. (2013). Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease. PLoS ONE 8:e81989. doi: 10.1371/journal.pone.0081989.
21. Kalueff, A. V., and Tuohimaa, P. (2007). Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr. Opin. Clin. Nutr. Metab. Care 10, 12-19. doi: 10.1097/MCO.0b013e328010ca18.
22. Llewellyn, D. J., Lang, I. A., Langa, K. M., Muniz-Terrera, G., Phillips, C. L., Cherubini, A., et al. (2010). Vitamin D and risk of cognitive decline in elderly persons. Arch. Intern. Med. 170, 1135-1141. doi: 10.1001/archinternmed.2010.173.
23. Matthews, F. E., Arthur, A., Barnes, L. E., Bond, J., Jagger, C., Robinson, L., et al. (2013). Medical Research Council Cognitive Function and Ageing Collaboration. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 382, 1405-1412. doi: 10.1016/S0140-6736(13)61570-6.
24. McShane, R., Areosa Sastre, A., and Minakaran, N. (2006). Memantine for dementia. Cochrane Database Syst. Rev. CD003154. doi: 10.1002/14651858.CD003154.pub5.
25. Moon, M., Song, H., Hong, H. J., Nam, D. W., Cha, M. Y., Oh, M. S., et al. (2013). Vitamin D-binding protein interacts with Abeta and suppresses Abeta-mediated pathology. Cell Death Differ. 20, 630-638. doi: 10.1038/cdd.2012.161.
26. Prybelski, R., Agrawal, S., Krueger, D., Engelke, J. A., Walbrun, F., and Binkley, N. (2008). Rapid correction of low vitamin D status in nursing home residents. Osteoporos. Int. 19, 1621-1628. doi: 10.1007/s00198-008-0619-x.
27. Schrötter, A., Magraoui, F. E., Gröttrup, B., Wiltfang, J., Heinsen, H., Marcus, K., et al. (2013). Early diagnosis of neurodegenerative diseases-the long awaited Holy Grail and bottleneck of modern brain research-19th HUPO BPP workshop: May 22-24, 2013, Dortmund, Germany. Proteomics 13, 2938-2941. doi: 10.1002/pmic.201370164.
28. Stein, M. S., Scherer, S. C., Ladd, K. S., and Harrison, L. C. (2011). A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. J. Alzheimers Dis. 26, 477-484. doi: 10.3233/JAD-2011-110149.
29. Sutherland, M. K., Somerville, M. J., Yoong, L. K., Bergeron, C., Haussler, M. R., and McLachlan, D. R. (1992). Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res. Mol. Brain Res. 13, 239-250. doi: 10.1016/0169-328X(92)90032-7.
30. Vellas, B., and Aisen, P. S. (2010). Early Alzheimer's trials: new developments. J. Nutr. Health Aging 14, 293. doi: 10.1007/s12603-010-0064-3.
31. Wang, L., Hara, K., Van Baaren, J. M., et al. (2012). Vitamin D receptor and Alzheimer's disease: a genetic and functional study. Neurobiol. Aging 33, 1844.e1-1844.e9. doi: 10.1016/j.neurobiolaging.2011.12.038.